Aktis Oncology (AKTS)
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat v...
- Open
- 24.330
- High
- 25.000
- Low
- 24.000
- Prev. Close
- 24.000
- Volume
- 226.36K
- Turnover
- 5.51M
- Avg Price
- 24.349
- Bid/Ask Ratio
- --
- Amplitude
- 4.17%
- 52wk High
- 34.190
- Volume Ratio
- 0.91
- Turnover Ratio
- 1.28%
Aktis Oncology Analyst Rating
View moreForecast & Rating
Aug 19, 2026Price forecast
$34.8144.63%
Forecast & RatingStrong buy
9analysts
- Strong buy88.89%
- Buy11.11%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Aug 20 at 06:06 AM
Aktis Oncology (NASDAQ:AKTS) Upgraded to Strong-Buy at BMO Capital Markets
- Global Report · Aug 18 at 05:12 AM
The Hidden Corners of Capital: AI Pivots, Bankruptcies, and the Survival of the Uncategorized
- Market Beat · Aug 13 at 03:41 PM
Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations
- Global Report · Aug 12 at 05:12 AM
Market Misfits of 2026: Crypto Fines, Delisted Zombies, and Sneeze-Inducing ETFs
- Global Report · Aug 8 at 04:20 AM
Capital Rotates to Yield ETFs and Niche SPACs in Fragmented Market
- Simplywall · Jul 24 at 12:03 AM
Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value?
